Electreon Announces Extension of World’s First Wireless Electric Road for Trucks and Buses
11.4.2022 10:00:00 EEST | Business Wire | Press release
Electreon (TASE: ELWS.TA), the leading provider of wireless and in-road wireless electric vehicle (EV) charging technology, today announced the one year extension of the Smartroad Gotland pilot project in Sweden. The €2 million ($2.17 million) budget for the extension is funded by the Swedish Transport Administration and includes an upgrade of 400 m of the existing installation. Electreon will also extend the run of the electric airport shuttle bus—the shuttle will continue to undergo testing and simultaneously be available for commercial rides, and will open to the public in the summer of 2022. Government stakeholders, commercial fleet operators, and businesses interested in the technology are welcome to visit the project site and learn more about the project.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220411005166/en/
Electreon has successfully demonstrated the operation of Electric Road Systems at scale utilizing a 40-ton e-truck and a commercial passenger e-bus. (Photo: Business Wire)
“The team at Smartroad Gotland is excited for the one year extension of this project and for the opportunity to demonstrate the continued endurance of our wireless charging technology in Swedish weather,” said Håkan Sundelin, director of the Nordic Region at Electreon and project manager for Smartroad Gotland. “The planned large scale electric road pilot in Sweden, in addition to the French government’s decision to fund pilots for wireless charging roads, shows high demand for Electreon’s technology in Europe.''
Jan Pettersson, program manager of electrification, Swedish Transport Administration said, “We are very positive about the opportunity to test higher wireless charging performance, as well as road durability. Now that the corona restrictions have eased, we are also looking forward to spreading the knowledge from the project more widely.”
As part of the project extension, Electreon will increase the capacity of its receivers to transfer energy to approximately 30 kW and examine a new generation of its technology. This will demonstrate how the wireless charging infrastructure can be upgraded to meet evolving needs over time. Electreon will also deploy its software capabilities, such as its billing feature, which enables the Company to invoice vehicle subscribers using the Electric Road System.
After the upgrade is complete, the long-haul e-truck and commercial passenger e-bus, that have now been utilizing the wireless charging infrastructure for one year as part of this project, will undergo continued testing. The Swedish National Road and Transport Research Institute (VTI) will perform third-party endurance and stress tests to verify that Electreon’s technology and charging coils are unaffected by road construction and heavy-duty truck use. Electreon’s wireless charging technology is designed to be future proof, and this project will continue to prove that Electreon offers long-term performance with minimal maintenance. Additional third-party endurance tests of Electreon’s wireless charging technology are currently being performed as part of the BASt project in Germany and the Arena of the Future project in Italy.
To date, Electreon’s patented technology has been integrated with a wide range of vehicles, as part of its ongoing collaborations with auto manufacturers including Renault, Stellantis, Iveco, and Volkswagen. In February 2022, Electreon announced it was awarded a Michigan Department of Transportation (MDOT) contract for the first public Electric Road System for wireless EV charging in the U.S. In November 2021, Electreon’s wireless charging technology was named one of TIME’s 100 Best Inventions of 2021.
About Electreon
Electreon is the leading provider of wireless charging solutions for electric vehicles (EVs), providing end-to-end charging infrastructure and services to meet the needs and efficiency demands of shared, public and commercial fleet operators and consumers. The company’s proprietary inductive technology dynamically (while in motion) and statically (while stopped) charges EVs quickly and safely, eliminating range anxiety, lowering total costs of EV ownership, and reducing battery capacity needs—making it one of the most environmentally sustainable, scalable, and compelling charging solutions available today. Electreon works with cities and fleet operators on a charging as a service (CaaS) platform that enables cost-effective electrification of public, commercial, and autonomous fleets for smooth and continuous operation. For more information, visit electreon.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220411005166/en/
Contact information
Media
Janine Ward
On behalf of Electreon
electreon@antennagroup.com
313-536-7806
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release
OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202613.6.2026 00:31:00 EEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 19:36:00 EEST | Press release
IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
